301.42

2.14% -6.58

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $301.42, with a volume of 335.34K. It is down -2.14% in the last 24 hours and up +2.95% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Previous Close:

$308.00

Open:

$308.26

24h Volume:

335.34K

Relative Volume:

0.69

Market Cap:

$13.29B

Revenue:

$2.76B

Net Income/Loss:

$1.11B

P/E Ratio:

13.24

EPS:

22.77

Net Cash Flow:

$898.10M

1W Performance:

+2.32%

1M Performance:

+2.95%

6M Performance:

-26.48%

1Y Performance:

+13.29%

1-Day Range:

$301.23

$313.35

1-Week Range:

$290.02

$313.35

52-Week Range:

$263.56

$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1153)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,305

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UTHR United Therapeutics Corp	301.42	13.29B	2.76B	1.11B	898.10M	22.77
ZTS Zoetis Inc	159.27	70.23B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.74	48.23B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.36	48.22B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.93	18.57B	16.54B	-1.64B	749.00M	-1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025

May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com UK

May 07, 2025

May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025

May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025

May 02, 2025

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.

May 02, 2025

US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex

May 02, 2025

BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada

May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus

May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus

May 01, 2025

United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus

May 01, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus

May 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025

Avepoint, Meta, United Therapeutics - TradingView

May 01, 2025

United Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 01, 2025